Crystal Research Releases Executive Report Detailing CytoCore Inc. Prospects.

Company Breaks Ground with Reproductive Cancer Diagnostics and Treatment

CHICAGO -- Second graph, company name should read: Crystal Research Associates (sted Crystal Springs Research Associates)

The corrected release reads:

CRYSTAL RESEARCH RELEASES EXECUTIVE REPORT DETAILING CYTOCORE INC. PROSPECTS

Company Breaks Ground with Reproductive Cancer Diagnostics and Treatment

CytoCore, Inc., (OTCBB:CYCR) today announced the release of a comprehensive Crystal Research Associates executive report assessing product development and market potential for the late-stage bio-scientific Company's suite of diagnostic products, slated for worldwide distribution in the screening and treatment of cervical, uterine and endometrial cancers.

Of particular note for biotech investors, potential strategic partners and industry analysts, the 68-page Executive Informational Overview report is now available at websites for both Crystal Research Associates (www.crystalra.com) and CytoCore (www.CytoCoreInc.com).

Highlights from the report include:

* Detailed financial data, market profiling and projected potential for the distribution of CytoCore's suite of endometrial, uterine and cervical diagnostic and treatment products worldwide.

* Delineation of the InPath[TM] System product line for improved early detection and treatment of cervical cancer, for which some 180 million tests are administered globally each year at a cost of $5 to $6 billion.

* Delineation of lab results and other progress pertaining to CytoCore's new EndoScan[TM], the first-ever early screening test for uterine cancer, of which some 40,000 cases are diagnosed annually in the U.S. alone.

* The notably affordable price point and aggressive timeline for clinical trials and distribution of CytoCore products.

* A strong commitment to corporate and capital restructuring, reflected in turnaround financial data and a newly assembled executive team whose depth of market experience and medical expertise position the company ideally for global distribution starting early in 2007.

* CytoCore's proprietary partnership with Dr. George Gorodeski, the Medical Advisory Board's director whose P2X7 bio-marker and other medical innovations have been licensed to the Company.

* The Company's rich patent portfolio, strategic research partnerships and technology transfer agreements in the area of reproductive cancer detection and treatment.

"Crystal Research's report lays out in thorough detail CytoCore's considerable scientific assets, global business potential and go-to-market plan," said Dr. Augusto Ocana, chief executive officer and director. "We're positioned to distribute a cutting-edge suite of medical products for routine office early detection, diagnoses and treatment of pervasive cancers that today kill hundreds of thousands of women worldwide every year."

For further information, visit www.CytoCoreInc.com

About CytoCore Inc.

CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath[TM] System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com

Dr. George Gorodeski has a significant financial interest in this research consisting of equity and fees from the Company as a consultant and Director of the Scientific Advisory Board of CytoCore. Dr. Gorodeski's invention licensed to CytoCore may generate royalty income for Dr. Gorodeski, for University Hospital Case Medical Center of Cleveland.

Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath[TM] System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.